BEVERLY, MA--(Marketwire - June 23, 2010) - INVO Bioscience, Inc. (OTCBB: IVOB), a medical device company focused on treatment options for patients diagnosed with infertility, announced today the INVO has been launched in Panama and Nicaragua.
INVO Bioscience attended the Congreso Central Americana de Ginecologia y Obstetricia in Nicaragua where INVO training and INVO initial cases were performed. Results from the initial patients have confirmed a 33% pregnancy rate.
INVO training was also performed in Panama in April. Five couples were treated during the procedural training resulting in 3 confirmed ongoing pregnancies.
INVO Bioscience's patented product, the INVOcell, allows for vaginal incubation of eggs, sperm and early embryo development during the infertility treatment process. "These initial cases are showing the same promise for the future sales of INVO in these Latin American countries," said INVO Bioscience's CEO, Kathleen Karloff.
About INVO Bioscience
INVO Bioscience (IVOB) is a medical device company, headquartered in Beverly, Massachusetts, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. The company's lead product, the INVOcell, is a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman's vaginal cavity. The company was founded by Claude Ranoux, MD, a noted expert in the field of reproductive health, infertility and embryology. For more information, please visit www.invobioscience.com.
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.